A Phase 2 Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, BRCA2, PALB2, and CHEK2
一项针对携带 ATM、BRCA1、BRCA2、PALB2 和 CHEK2 致病性变异的晚期胰腺癌患者的 Niraparib II 期试验
期刊:Clinical Cancer Research
影响因子:10.2
doi:10.1158/1078-0432.CCR-24-3766
Huffman, Brandon M; Diossy, Miklos; Yurgelun, Matthew B; Horick, Nora; Li, Yvonne Y; Crowdis, Jett; Nguyen, Huy; Parmar, Kalindi; Kochupurakkal, Bose S; Vonk, Leonard; Lam, Helen; Ramsey, Kaitlyn; Andrews, Elizabeth; Loeb, Sarah C; Culnane, Leigh; Biller, Leah H; Bullock, Andrea J; Enzinger, Andrea; Giannakis, Marios; Jackson, Nadine A; Ng, Kimmie; Nowak, Jonathan A; Patel, Anuj K; Perez, Kimberly J; Rattani, Ahmed; Rubinson, Douglas A; Schlechter, Benjamin L; Singh, Harshabad; Cai, Mingyang; Raghavan, Srivatsan; Clark, Jefferey W; Peters, Mary Linton; Weipert, Caroline M; Wolpin, Brian M; D'Andrea, Alan D; Shapiro, Geoffrey I; Aguirre, Andrew J; Szallasi, Zoltan; Cleary, James M
肿瘤
PALB2
肿瘤免疫
BRCA2
ATM
BRCA1
胰腺癌